Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 11, 2026

OP Pohjola's Financial Statements Bulletin 1 January–31 December 2025: Another strong year for OP Pohjola – operating profit EUR 2,269 million

View original at globenewswire.com
OP Pohjola's Financial Statements Bulletin 1 January–31 December 2025: Another strong year for OP Pohjola – operating profit EUR 2,269 million OP Pohjola Financial Statements Bulletin Stock Exchange Release 11 February 2026 9.00 am EET OP Pohjola's Financial Statements Bulletin 1 January–31 December 2025: Another stron…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Operating profit for 2026 is expected to be at a good level but lower than that for 2025

    80% confidence

  • OP Pohjola's operating profit for 2025 was EUR 2,269 million, the second-best figure in our history

    80% confidence

  • Finland's largest provider of corporate loans, we support the growth and success of Finland and its private sector

    80% confidence

  • Bigger and stronger OP cooperative banks will strengthen our ability to serve our owner-customers and corporate customers on a broader, more versatile basis around Finland

    80% confidence

  • OP Pohjola is one of the most financially solid large banks in Europe

    80% confidence

  • Our good financial performance would enable a more than tenfold increase in OP bonuses earned from home, property and motor vehicle insurance in 2026, providing total additional benefit of more than EUR 30 million

    80% confidence

  • In 2025, more than 80% of our personnel participated in AI training, and almost 13,000 of our employees now use an AI assistant

    80% confidence

  • We are the clear market leader in home loans in Finland

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com